MedTrace Logo

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NCT02958358 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-11-15

No results posted yet for this study

Summary

The investigators are doing this research study to find out how blood flow changes in the lungs of people with pulmonary hypertension before and after treatment with ambrisentan (sold under the brand name Letairis). The investigators hope that knowing about these differences will help us to better understand pulmonary hypertension and find new ways to diagnose it earlier.

Conditions

Interventions

OTHER

CT imaging, functional PET imaging

Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Robert Scott Harris, M.D.

    lead OTHER

Principal Investigators

  • Robert S Harris, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958358 on ClinicalTrials.gov